Abstract
Morinda lucida Benth has been traditionally reported as a remedy for the treatment of cancer as well as Leukemia in Africa. Therefore, this study was aimed at screening fractions of M. lucida for potential anti-leukemia constituents and activities in mice. leukemia was induced with intra-peritoneal administration of benzene. Fractions of M. lucida were administered by oral gavaging in mice and screened for anti-leukemia and anti-clastogenic activities. The liver sections were assessed for hepatoprotective activity and possible anti-leukemia compounds in fractions were analysed using GC-MS. Docking analysis was done to understand the mechanism of anti-leukemic activity. Significant ( p < 0.05) anti-leukemic activity was observed in the ethyl acetate and n-butanol fractions while prevention of chromosomal and liver damage was exhibited by all the fractions. GC-MS analysis of the fractions revealed anti-leukemic constituents. The identified constituents showed promising pharmacokinetic properties and inhibitory potential against certain proteins involved in cancer development. Overall, the anti-leukemic activity observed in this study might be attributed to the antioxidant, apoptotic induction, cell cycle control, and anti-inflammatory properties of M. lucida fractions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
